Multiple regression models on prediction of steroid-refractory GVHD
. | Model 1 . | Model 2 . | Model 3 . | |||
---|---|---|---|---|---|---|
OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | |
Gut GVHD stage 1 | 1 | 1 | ||||
Gut GVHD stage 2 | 3.06 (0.77-12.1) | .11 | 1.28 (0.22-7.52) | .78 | ||
Gut GVHD stage 3 | 13.7 (2.41-78.2) | .003 | 6.88 (0.95-49.5) | .056 | ||
Calprotectin ≥ 100 μg/g | 16.1 (1.76-147.6) | .014 | 16.8 (1.70-165.3) | .016 | ||
α1-AT ≥ 1.5 mg/g dw | 4.10 (0.98-17.1) | .053 | 2.84 (0.60-13.4) | .19 | ||
Model LR | 11.65 | 21.95 | 26.22*† | |||
c index | 0.747 | 0.833 | 0.863 | |||
Corrected c index | 0.733 | 0.827 | 0.826 |
. | Model 1 . | Model 2 . | Model 3 . | |||
---|---|---|---|---|---|---|
OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | |
Gut GVHD stage 1 | 1 | 1 | ||||
Gut GVHD stage 2 | 3.06 (0.77-12.1) | .11 | 1.28 (0.22-7.52) | .78 | ||
Gut GVHD stage 3 | 13.7 (2.41-78.2) | .003 | 6.88 (0.95-49.5) | .056 | ||
Calprotectin ≥ 100 μg/g | 16.1 (1.76-147.6) | .014 | 16.8 (1.70-165.3) | .016 | ||
α1-AT ≥ 1.5 mg/g dw | 4.10 (0.98-17.1) | .053 | 2.84 (0.60-13.4) | .19 | ||
Model LR | 11.65 | 21.95 | 26.22*† | |||
c index | 0.747 | 0.833 | 0.863 | |||
Corrected c index | 0.733 | 0.827 | 0.826 |